For patients with myelodysplastic syndrome, or MDS, their therapy options vary considerably depending on their prognosis and risk of developing AML. Today we discuss risk stratification systems and their rationale, and consider their utility in clinical practice. To answer our questions on this topic, we welcome Professor Detlaf Haase, medical director of the special diagnostic laboratories at the clinic for hematology & medical oncology in at the University Medical Center in Göttingen, Germany.

References

• Greenberg, et al. Blood. 2012 Sep 20; 120(12): 2454–2465
• Montalban-Bravo & Garcia-Manero. Am J Hematol. 2018 Jan;93(1):129-147

This series is supported by educational grants from Servier Pharmaceuticals LLC and Takeda, who have had no influence on the content or choice of faculty.